FGFR1 and breast cancer: Our results advance in the task of finding a therapeutic scenario and a patient sub-population where FGFR inhibitors would deserve clinical investigation: HR+ breast cancer patients with amplification and/or overexpression of FGFR1 upon progression to aromatase inhibitors.